Sindrome di Lennox-Gastaut
Revisione paritaria di Dr Krishna Vakharia, MRCGPUltimo aggiornamento di Dr Colin Tidy, MRCGPUltimo aggiornamento 1 Set 2023
Rispetta le linee guida editoriali
- ScaricaScarica
- Condividi
- Language
- Discussione
- Versione audio
- Add to preferred sources on Google
Professionisti Medici
Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find one of our articoli sulla salute more useful.
In questo articolo:
Synonyms: childhood epileptic encephalopathy
Continua a leggere sotto
What is Lennox-Gastaut syndrome?
The Lennox-Gastaut syndrome is characterised by multiple types of epileptic seizures, a characteristic electroencephalogram (EEG) with generalised slow spike-and-wave discharges, psychomotor delay and behavioural disorders.
The onset is usually before the age of 8, with a peak between the ages of 3 and 5 years. Late cases occurring in adolescence and early adulthood have rarely been reported.1
The most common seizure types are tonic-axial, atonic, and absence seizures; however, myoclonic, generalised tonic-clonic, and partial seizures may also occur.
Drop attacks are a frequently recognisable seizure type and also the most dangerous physically, severely limiting quality of life.2
Seizures are often resistant to treatment.
Lennox-Gastaut syndrome can be classified as either idiopathic (25% of the total) or symptomatic (75%).
In idiopathic, normal psychomotor development occurs prior to the onset of symptoms and no neurological or neuroradiological abnormalities are found.
Symptomatic cases are due to diverse cerebral conditions, which are usually bilateral, diffuse, or multifocal, involving cerebral grey matter.3
Examples of underlying disorders responsible for symptomatic Lennox-Gastaut syndrome include encephalitis, meningitis, tuberous sclerosis, brain malformations, birth injury, frontal lobe lesions and trauma.
How common is Lennox-Gastaut syndrome? (Epidemiology)1
Torna ai contenutiLennox-Gastaut syndrome represents approximately 3% to 5% of all childhood onset epilepsies. In population‐based childhood epilepsy incidence cohorts, only up to 0.9% of patients are identified with Lennox-Gastaut syndrome when epilepsy is diagnosed.
Other defining characteristics such as multiple seizure types and EEG features evolve over time.
The prevalence of Lennox-Gastaut syndrome was estimated at 26 per 100,000 in a regional US study.
Continua a leggere sotto
Lennox-Gastaut syndrome symptoms (presentation)4
Torna ai contenutiLanguage is frequently affected, with both slowness in ideation and expression in addition to difficulties of motor dysfunction. Severe behavioural disorders (eg, hyperactivity, aggressiveness and autistic tendencies) and personality disorders are nearly always present. There is also a tendency for psychosis to develop with time.
The tonic type of seizure is seen in all patients but may not be present at the time of its onset. Atypical absence seizures (with gradual onset and termination) are the second-most common type of epileptic activity, but is difficult to diagnose clinically in patients with diminished cognition. Prolonged atypical absences are seen in 66% of the patients with altered consciousness, which is periodically interrupted by episodes of tonic seizures. These non-convulsive episodes may last for hours to weeks in severe cases (non-convulsive status epilepticus).
Atonic and myoclonic seizures have also been recorded. Drop attacks are also common (more than 50%), but not a pathognomonic clinical manifestation. Other types of seizures more commonly seen in later stages of the disease include focal seizures, generalized tonic-clonic seizures, or unilateral clonic seizures.
There is an increased risk of intellectual disability with a history of non-convulsive status epilepticus, a diagnosed case of West syndrome, any identifiable aetiology, and early age of onset. Cognitive decline is secondary to epilepsy itself, like all other epileptic encephalopathies or may be due to abnormal neuronal connections and the side effects of medications.
Diagnosi differenziale
Torna ai contenutiOther epileptic encephalopathies.5
Epilepsy with general learning disability.
Juvenile myoclonic epilepsy.
Myoclonic-astatic epilepsy.6
Continua a leggere sotto
Indagini
Torna ai contenutiBlood tests to exclude a metabolic cause.
Magnetic resonance imaging of the brain.
Electroencephalogram.
Genotyping.
Lennox-Gastaut syndrome treatment and management
Torna ai contenutiThe majority of cases remain refractory to medical management and require polytherapy, and only 10% of cases are estimated to undergo full seizure remission with available therapies.7
Randomised controlled trials of monotherapy and comparison of add-on anti-seizure medications are currently lacking. However, a Cochrane review found high-certainty evidence for overall seizure reduction with add-on lamotrigine and rufinamide.1
Linee guida dell'Istituto Nazionale per l'Eccellenza nella Salute e nell'Assistenza (NICE)8
Ensure that people with Lennox–Gastaut syndrome have an adult or paediatric neurologist with expertise in epilepsy involved in their care.
First-line treatment:
Consider sodium valproate as first-line treatment. Sodium valproate should be used with caution in women and girls, but it is recommended as first-line treatment for Lennox–Gastaut syndrome because of the severity of the syndrome and the lack of evidence for other effective first-line treatment options.
Take into account the likelihood of pregnancy and put in place a pregnancy prevention programme, if appropriate.
Nota dell'editore |
|---|
Dr Krishna Vakharia, 29 gennaio 2024 L'Agenzia per i Medicinali e i Dispositivi Medici (MHRA) ha pubblicato un aggiornamento sull'uso del valproato di sodio a causa dei rischi noti associati alla gravidanza e ai difetti alla nascita; e dei rischi crescenti emergenti di disturbi neuroevolutivi osservati nei bambini i cui padri hanno assunto valproato nei 3 mesi prima del concepimento.9 Nuove linee guida affermano che: - Il valproato non dovrebbe essere iniziato in nuovi pazienti - sia maschi che femmine - di età inferiore ai 55 anni. - Due specialist possono considerare e documentare indipendentemente che non esiste un altro trattamento efficace o tollerato, oppure ci sono motivi validi per cui i rischi riproduttivi non si applicano se si considera il valproato di sodio. - Alla loro prossima revisione specialistica annuale, le donne in età fertile e le ragazze che assumono valproato dovranno essere valutate utilizzando il modulo aggiornato di Riconoscimento del Rischio Annuale del Valproato. Sarà necessaria una seconda firma di uno specialista se il paziente deve continuare con il valproato; tuttavia, le revisioni annuali successive richiederanno solo un specialista. - I team di medicina generale e farmacia dovrebbero continuare a prescrivere e dispensare il valproato e, se necessario, offrire ai pazienti un rinvio a uno specialista per discutere le opzioni di trattamento. Il valproato dovrebbe essere dispensato nella confezione originale completa del produttore. - Segnala le sospette reazioni avverse ai farmaci associate al valproato su una Scheda Gialla. I pazienti dovrebbero essere istruiti a non interrompere l'assunzione di valproato senza il consiglio di uno specialista. Questo perché la loro condizione potrebbe peggiorare senza trattamento. Dr Krishna Vakharia, 13th September 2024 The Medicines and Healthcare products Regulatory agency has issued an alert to the use of valproate in men around the time of conception. 10A study has found an increased risk of neurodevelopmental disorders in their children. |
Trattamento di seconda linea:
If first-line treatment is unsuccessful, consider lamotrigine as a second-line monotherapy or add-on treatment for people with Lennox–Gastaut syndrome.
Third-line treatment:
If second-line treatment is unsuccessful, consider the following as third-line add-on treatment options for people with Lennox–Gastaut syndrome: cannabidiol in combination with clobazam (if the child is over 2 years), clobazam, rufinamide, or topiramate.
Further treatment options
If seizures continue with third-line treatments, consider a ketogenic diet as an add-on treatment under the supervision of a ketogenic diet team.
If all other treatment options for Lennox–Gastaut syndrome are unsuccessful, consider felbamate as add-on treatment under the supervision of a neurologist with expertise in epilepsy.
Other treatment considerations
The following medications may exacerbate seizures in people with Lennox–Gastaut syndrome: carbamazepine, gabapentin, lacosamide, oxcarbazepine, phenobarbital, pregabalin, tiagabine, vigabatrin.
Chirurgico4
Surgical options for Lennox-Gastaut syndrome include corpus callosotomy, vagus nerve stimulation, and focal cortical resection.
Corpus callosotomy: the resection of the anterior 4/5th is sufficient to produce effective results, but a 10% lower response rate as compared to those with total resection of the corpus callosum.
Vagus nerve stimulation: reserved for patients with medically refractory seizures where surgery is not the option. It is effective in all types of seizures and adverse effects are much less as compared to corpus callosotomy. The most common side effects are hoarseness of voice, dysphagia, dyspneoa, and coughing.
Cortectomy/lobar dissection: selective dissection of the cortex.
Other options are gamma knife callosotomy, deep brain stimulation, and multiple subpial transactions.
Complicazioni
Torna ai contenutiBehavioural disturbances.
Injuries or death resulting from a seizure.
Renal, cardiac, or metabolic complications resulting from a ketogenic diet.
Prognosi4
Torna ai contenutiFeatures of typical Lennox-Gastaut syndrome will evolve over time.
The variety and frequency of seizures decrease over time, and so does their severity.
Generalised paroxysmal fast activity on EEG will typically persist into adulthood, while slow spike-wave complexes will remain in a minority of cases.
Cognitive and behavioural disturbances will remain as an adult in most with Lennox-Gastaut syndrome .
The long-term outcome is variable, from normally functioning individuals to severe learning difficulties and treatment-resistant seizures in 47%-76% of cases, and these will need special home or institutional care.
Exclusive updates for healthcare professionals
Stay informed with the latest clinical updates, professional insights, and evidence-based guidance. The Patient Pro newsletter curates essential content for healthcare professionals—delivered straight to your inbox.
By subscribing you accept our Informativa sulla Privacy. Puoi annullare l'iscrizione in qualsiasi momento. Non vendiamo mai i tuoi dati.
Ulteriori letture e riferimenti
- Amrutkar C, Riel-Romero RM; Lennox Gastaut Syndrome. StatPearls, July 2023.
- Brigo F, Jones K, Eltze C, et al; Anti-seizure medications for Lennox-Gastaut syndrome. Cochrane Database Syst Rev. 2021 Apr 7;4(4):CD003277. doi: 10.1002/14651858.CD003277.pub4.
- VanStraten AF, Ng YT; Update on the management of Lennox-Gastaut syndrome. Pediatr Neurol. 2012 Sep;47(3):153-61. doi: 10.1016/j.pediatrneurol.2012.05.001.
- Markand ON; Lennox-Gastaut syndrome (childhood epileptic encephalopathy).; J Clin Neurophysiol. 2003 Nov-Dec;20(6):426-41.
- Jahngir MU, Ahmad MQ, Jahangir M; Lennox-Gastaut Syndrome: In a Nutshell. Cureus. 2018 Aug 13;10(8):e3134. doi: 10.7759/cureus.3134.
- McTague A, Cross JH; Treatment of epileptic encephalopathies. CNS Drugs. 2013 Mar;27(3):175-84. doi: 10.1007/s40263-013-0041-6.
- Kaminska A, Oguni H; Lennox-Gastaut syndrome and epilepsy with myoclonic-astatic seizures. Handb Clin Neurol. 2013;111:641-52. doi: 10.1016/B978-0-444-52891-9.00067-1.
- Purcarin G, Ng YT; Experience in the use of clobazam in the treatment of Lennox-Gastaut syndrome. Ther Adv Neurol Disord. 2014 May;7(3):169-76. doi: 10.1177/1756285614521314.
- Epilessie nei bambini, giovani e adulti; Linee guida NICE (2022 - ultimo aggiornamento gennaio 2025)
- Valproato (Belvo, Convulex, Depakote, Dyzantil, Epilim, Epilim Chrono o Chronosphere, Episenta, Epival e Syonell▼): nuovi materiali informativi e di sicurezza per supportare le misure regolamentari in uomini e donne sotto i 55 anni; Agenzia di regolamentazione dei medicinali e dei prodotti sanitari, GOV.UK (gennaio 2024)
- Uso del valproato negli uomini: come precauzione, uomini e loro partner dovrebbero usare un metodo contraccettivo efficace; Agenzia regolatoria dei medicinali e dei prodotti sanitari, GOV.UK (settembre 2024)
Continua a leggere sotto
About the authorView full bio

Dr Colin Tidy, MRCGP
Medico di base, Autore medico
MBBS, MRCGP, MRCP (Paediatrics), DCH
Dr Colin Tidy is an NHS Doctor, based in Oxfordshire.
About the reviewerView full bio

Dr Krishna Vakharia, MRCGP
Chief Medical Officer for Health, Optum UK
MBChB, MRCGP(2013), BMedSci (hons), DFSRH, DRCOG, PGDipDerm (Distn)
Dr Krishna Vakharia is an NHS GP. She is also a regular examiner for the postgraduate Diploma in Practical Dermatology at Cardiff University as well as being the Chief Medical Officer for health at Optum UK.
Storia dell'articolo
Le informazioni su questa pagina sono scritte e revisionate da clinici qualificati.
Prossima revisione prevista: 30 ago 2028
1 Set 2023 | Ultima versione

Chiedi, condividi, connettiti.
Esplora le discussioni, fai domande e condividi esperienze su centinaia di argomenti di salute.

Non ti senti bene?
Valuta i tuoi sintomi online gratuitamente